You read that a study “worked better in women” or “only helped people over 60.” Should you trust that difference? Often the careful answer is: not yet. A difference found in one slice of a study’s participants can be real, but it can also appear by chance, especially when researchers checked many slices or chose which slices to check after seeing the data.
This guide shows you how to judge whether a subgroup finding was planned and reported carefully, or whether it should be treated as a lead for future research. At the end, you will find a printable checklist.
Educational information only. This article does not diagnose conditions, recommend treatments, or replace advice from a qualified health professional. Do not start, stop, or change any medicine or supplement based on a subgroup finding. If you have a medical emergency, contact your local emergency services.
The Decision You Are Facing
When you see a subgroup claim, you are deciding how much weight to give it. Our editorial framework offers three reasonable choices:
- Treat it as supported when it was planned in advance, reported clearly, and consistent with the study’s main results.
- Treat it as a possibility when it was planned but has limits, such as small numbers or uncertain estimates.
- Treat it as a hypothesis only when it was found after the fact, is one of many comparisons, or is not clearly reported.
The rest of this page helps you decide which of these applies.
First, What Is a Subgroup Finding?
A subgroup is a smaller group of participants within a study, defined by a shared trait such as age, sex, or starting health status. A subgroup analysis asks whether the results look different in that smaller group than in the study as a whole.
Randomized trials are expected to name their main outcomes before the study begins. The CONSORT 2025 reporting guideline asks trial reports to describe “pre-specified primary and secondary outcomes” (item 14). The guideline treats subgroup analyses as additional analyses (item 21d). They can be useful, but they carry extra risks of misleading results.
A Quick Process Map
Use these five steps in order whenever you meet a subgroup claim:
- Find the plan. Was this subgroup named in the trial’s protocol or statistical analysis plan before results were known?
- Count the comparisons. How many subgroups were checked in total?
- Check the labels. Did the report say which analyses were planned ahead of time and which were not?
- Look at the numbers. How many people were in the subgroup, and how wide is the uncertainty?
- Read the limitations. Did the authors discuss the risk of chance findings from multiple analyses?
Why Can a Subgroup Difference Appear by Chance?
Running many separate comparisons on the same data is called multiplicity. A 2022 review in the journal Eye explains that “simultaneous subgroup analyses create multiplicity, inflating the defined nominal significance level (alpha) which increases the likelihood of spurious and compelling results by chance alone.”
An illustrative example (our own arithmetic, not data from any study): suppose a treatment truly has the same effect in everyone, and researchers check 20 separate subgroups, each using the common 5% threshold for statistical significance. If those checks were fully independent, the chance that at least one would look “significant” anyway is about 64%. That figure is 1 minus 0.95 multiplied by itself 20 times. Real subgroup analyses are rarely fully independent, so the exact figure differs. The point stands: more looks mean more chances for a false alarm.
Subgroups also contain only part of a study’s participants, so their results rest on fewer people. CONSORT 2025 asks authors to address “imprecision” and, if relevant, “multiplicity of analyses” when they describe a trial’s limitations (item 30).
Was the Subgroup Planned Before the Results Were Known?
This is the most important question. A prespecified analysis was written into the study plan before anyone saw the results. A post-hoc analysis was chosen after the data came in. Post-hoc findings are not automatically wrong, but they are more open to chance.
CONSORT 2025 asks trial reports to describe “methods for any additional analyses (e.g., subgroup and sensitivity analyses), distinguishing prespecified from post-hoc” (item 21d). It also asks them to report “any other analyses performed, including subgroup and sensitivity analyses, distinguishing pre-specified from post-hoc” (item 28).
What to look for: the words “prespecified,” “pre-planned,” “exploratory,” or “post hoc” near the subgroup result, and a link to the trial protocol or statistical analysis plan.
Can You See the Original Plan?
CONSORT 2025 asks trial reports to give the “name of trial registry, identifying number (with URL) and date of registration” (item 2), and to state “where the trial protocol and statistical analysis plan can be accessed” (item 3). The companion guideline, SPIRIT 2025, is a 34-item set of recommendations for reporting a trial’s protocol.
If you can find the protocol, compare it with the published paper. CONSORT 2025 asks authors to report “important changes to the trial after it commenced including any outcomes or analyses that were not prespecified, with reason” (item 10). A subgroup that appears in the paper but not in the plan, with no explanation, deserves extra caution.
Did the Authors Compare the Subgroups Directly?
Reporting a result inside each subgroup separately does not, by itself, show that the groups truly differ. Researchers can use a statistical check called an interaction test. The Eye review describes it this way: “The interaction test determines if treatment effects differ between different subgroups.”
What to look for: the phrase “test for interaction” or “interaction p-value” in the methods or results.
Does the Finding Fit the Bigger Picture?
The same Eye review points to other signs that make a subgroup finding more credible:
- A prespecified reason. A subgroup analysis is more credible “if planned based on a prespecified hypothesis.”
- Consistency in later studies. “The consistency of the subgroup effects in subsequent well-designed trials provide stronger credibility.”
- A sensible explanation. Effects are more predictable when “hypothesised based on a sound biological and clinical plausibility.”
CONSORT 2025 also asks for an “interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence” (item 29). If a news story highlights a subgroup finding but the study’s own discussion calls it exploratory or uncertain, trust the study’s own caution.
Where Can You Find Trial Records and Reporting Guidelines?
ClinicalTrials.gov is a public registry that offers a plain-language guide: How to Read Study Results. The CONSORT and SPIRIT guidelines, checklists, and explanation documents are available from the SPIRIT–CONSORT website.
Printable Subgroup Finding Checklist
Print this page or copy the list below. Answer each question with Yes, No, or Can’t tell.
Planning
- Was this subgroup named in the protocol or statistical analysis plan before results were known?
- Can I find the trial registry name, registration number, and a link to the protocol?
- Did the authors explain, with reasons, any changes to planned outcomes or analyses?
Reporting
- Does the report clearly label the subgroup analysis as prespecified or post-hoc?
- Does it say how many subgroups were analyzed in total?
- Did the authors use an interaction test to compare subgroups directly?
Size and Certainty
- How many participants were in the subgroup?
- Is an uncertainty range reported, and is it narrow or wide?
- Does the subgroup finding agree with the study’s main result, or contradict it?
Interpretation
- Do the authors discuss multiplicity or the risk of chance findings?
- Has the finding been repeated in later, well-designed studies?
- Does the summary or news coverage match the caution in the study itself?
How to read your answers: several “No” or “Can’t tell” answers suggest treating the subgroup finding as a hypothesis for future research, not as settled evidence.
Questions to Bring to a Health Professional
If a subgroup finding seems to apply to you, these questions can support a clear, informed conversation. Your clinician can put the evidence in the context of your own health:
- Was this subgroup result planned in advance, or discovered afterward?
- How many people like me were actually studied?
- Has this pattern been confirmed in other research?
- Does this finding change anything about my situation, or is it too early to say?
Sources and How We Used Them
- SPIRIT–CONSORT website and its CONSORT 2025 expanded checklist: descriptions of CONSORT 2025 and SPIRIT 2025, and the quoted wording of items 2, 3, 10, 14, 21d, 28, 29, and 30.
- Farrokhyar F, et al. “When to believe a subgroup analysis: revisiting the 11 criteria.” Eye, 2022: quoted on multiplicity, interaction tests, prespecified hypotheses, consistency, and plausibility.
- ClinicalTrials.gov: How to Read Study Results: provided as further reading on public trial records.
ClinicalStudyConnect.com is an independent educational publication. We do not sell products, and this page contains no product recommendations. It explains how to read research. It is not medical advice.